Argos Aims To Automate Cell-Based Cancer Therapy

Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip